Speakers and Videos

Dr. Jean-Bernard Durand


Dr. Durand is an Associate Professor in the Department of Cardiology at the University of Texas MD Anderson Cancer Center. He is also the Medical Director of Cardiomyopathy Services, Director of Cardiovascular Genetic Research, Director of Cardiology Fellowship Program, Clinical Assistant Professor of Medicine at Baylor College of Medicine, and staff of the Heart Failure/Heart Failure Transplant Service at St. Luke’s Episcopal Hospital.


Dr. Durand’s major research is dedicated to understanding the molecular genetics of cardiomyopathies, primarily the identification of genes responsible for cardiomyopathy of all etiologies. His work also focuses on defining the molecular mechanisms involved in chemotherapy-induced cardiomyopathy. Dr. Durand is the Founder of the World’s first heart failure program dedicated to cardiotoxicity and cancer, which includes the World’s largest database of DNA from patients with heart failure secondary to chemotherapy. He has future plans to perform genotyping to identify heart failure susceptibility genes which may predispose patients to develop left ventricular dysfunction. In addition, he has also developed a tissue bank for further expression studies to identify critical pathways which are common to cancer biology and cardiovascular biology. His areas of scientific interests also include genotyping single nucleotide polymorphisms of Tyrosine Kinase Inhibitor-related cardiomyopathy, and acute coronary syndromes in cancer patients with Thrombocytopenia.

[Watch Presentation]

Dr. Michael S. Ewer


Dr. Michael S. Ewer is the Special Assistant to the Vice President of Medical Affairs at The University of Texas MD Anderson Cancer Center. He is also a Professor in the Division of Internal Medicine at the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute. 

[Watch Presentation]

Dr. Paul Nathan


Dr. Paul Nathan is a pediatric Hematologist/Oncologist and Director of the AfterCare clinic in the Division of Pediatric Hematology/Oncology at the Hospital for Sick Children in Toronto. He is an Associate Professor of pediatrics and Health Policy, Management and Evaluation at the University of Toronto, and an adjunct scientist at the Institute for Clinical Evaluative Sciences. His research and clinical practice is focused on long-term outcomes in survivors of childhood cancer including the cardiac complications of cancer therapy. 


He is the principal investigator on a team grant focused on developing innovative imaging, biomarker and genetic methods for predicting risk for cardiac dysfunction in this population. His research is funded by CIHR, the Canadian Cancer Society, and the Ontario Institute for Cancer Research, among others.

[Watch Presentation]

Dr. Martin Myers


Dr. Martin Myers is a staff Cardiologist at the Sunnybrook Health Sciences Centre and a Professor of Medicine at the University of Toronto. His main research focus is in hypertension, with a special interest in automated blood pressure measurement. Dr. Myers is a member of the European Society of Hypertension Working Group on Blood Pressure Measurement and has served on national and international committees developing guidelines for blood pressure measurement. 

Dr. Peter Liu

MD, FRCPC - Keynote Speaker

Dr. Peter Liu is currently the Scientific Director of the University of Ottawa Heart Institute, and also Professor of Medicine and Physiology at the University of Toronto. He currently serves as the President of International Society of Cardiomyopathy & Heart Failure of World Heart Federation, and was the former Scientific Director of the Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research. He received his MD degree from University of Toronto, and postgraduate training at Harvard University. His laboratory investigates the causes and treatments of heart failure, role of inflammation and identification of novel biomarkers and interventions in cardiovascular disease. 


He has published over 300 peer reviewed articles in high impact journals, cited over 20,000 times, and received numerous awards in recognition of his research and scientific accomplishments. He has chaired or co-chaired scientific sessions of the Heart Failure Society of America, International Society of Heart Research and Human Proteomic Organization, amongst others. He is also champion for knowledge translation, integrating the cardiovascular prevention guidelines and healthy heart policy in Canada and internationally.

Dr. Edward T. H. Yeh


Dr. Edward T.H. Yeh received his medical degree from the University of California, Davis. In 1987, he was appointed Assistant Professor of Medicine at the Massachusetts General Hospital and Harvard Medical School. In 2000, he founded the Department of Cardiology at The University of Texas MD Anderson Cancer Center. Dr. Yeh established a new field called Onco-cardiology that specializes in providing comprehensive cardiac care to cancer patients. His laboratory made the seminal discovery that Topoisomerase 2b (Top2b) mediates anthracycline-induced cardiotoxicity. This finding heralds in a new age of personalized cardio-protection for patients undergoing chemotherapy. Dr. Yeh received grants from the National Institute of Health, Cancer Prevention Research Institute of Texas, and Department of Defense. 


He was a Massachusetts General Hospital/Upjohn Scholar, Arthritis Investigator of Arthritis Foundation, and Established Investigator of the American Heart Association. Dr. Yeh was elected to memberships in Academia Sinica, the Association of American Physicians, and the American Society for Clinical Investigation. He was selected as the Distinguished Alumnus of the University of California, Davis Medical School and has served for ten years as Associate Editor of Circulation. He was President of the Houston Cardiology Society and President of the Board of American Heart Association, Houston Chapter. He has been named America’s Top Cardiologist and Best Doctors in America.

Dr. Davinder S. Jassal


Dr. Davinder S. Jassal joined the University of Manitoba in 2006 as an Academic Clinician Scientist, where half of his time is devoted to patient care in the Coronary Care Unit and cardiac imaging and the other half devoted to translational research. Dr. Jassal is an Associate Professor of Medicine, Radiology and Physiology; Principal Investigator of the Cardiovascular Imaging Laboratory in the Institute of Cardiovascular Sciences at the St. Boniface General Hospital and Research Centre; Program Director of the Adult Cardiology Residency Training Program; Medical Director of the WRHA Coronary Care Unit; Co-director of the WRHA Cardiac CT and MRI programs; and Postgraduate Cardiology Research Director. Dr. Jassal holds the Heart and Stroke Foundation of Canada New Investigator. 


He was recently nationally awarded the Royal College of Physicians and Surgeons of Canada Mentor of the Year Award, Canadian Cardiovascular Society Young Investigator Award, the Liam Murphy Young Invesigator Award from the Department of Internal Medicine, and the University of Manitoba Rh Award for Outstanding Contributions to Scholarship and Research in the Health Sciences Category. Dr. Jassal has secured grant support from a total of 26 local, provincial and federal agencies amounting to 3.0 million dollars in funding. With over 350 peer reviewed publications consisting of original research, editorials, chapters, and abstracts, he has published in high impact journals including the New England Journal of Medicine, Circulation, Journal American College of Cardiology, and the European Heart Journal.

Dr. Marjan Boerma


Marjan Boerma received her PhD degree in Radiation Biology at the University of Leiden, in the Netherlands. Her PhD work involved the use of pre-clinical models to investigate biological mechanisms of radiation-induced heart disease (RIHD), a long-term side effect of radiation therapy of intrathoracic and chest wall tumors. She moved to the University of Arkansas for Medical Sciences (UAMS) in 2004 to continue her work on RIHD, first as a postdoctoral fellow and in 2006 as a tenure-track faculty. Currently Associate Professor in the Division of Radiation Health at UAMS, her lab receives funding from the American Cancer Society and the National Cancer Institute to identify biological mechanisms of and potential interventions in RIHD. 

Dr. Daniel Lenihan

Professor of Medicine; Director, Clinical Research Program, Vanderbilt Heart and Vascular Institute, Nashville, TN


Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc.  Conference Topic: International CardiOncology Society: 2014 Update


As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.